LONDON and PHOENIX, Ariz., September 13, 2022 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. ACUTEa clinical-stage diagnostics company dedicated to improving patient outcomes for cancer patients, announced today that the US Patent and Trademark Office has granted a new patent number 11,441,191, which forms the basis of the company’s intellectual property for its novel StemPrintER test.

The “Methods and Kits Composing Gene Signatures for Stratifying Breast Cancer Patients” patent covers the methodology behind the 20-gene StemPrintER test, which stratifies patients with early-stage breast cancer according to their risk of recurrence. The test is designed to measure the “sturdyness” of tumors, or how much they behave like stem cells, which can indicate the likelihood of cancer progression and response to standard treatment modalities. Studies have shown that StemPrintER is very prognostic, with ‘high stemness’ patients being up to 4 times more likely to experience distant recurrence than ‘low stemness’ patients.

“This is an important step forward for AccuStem. This addition to our intellectual property portfolio will enable us to commercialize and drive innovation in healthcare in the United States – one of our core commitments as a healthcare company,” said Wendy Blosser, AccuStem Chief Executive Officer .

About AccuStem

AccuStem is a clinical-stage diagnostics company dedicated to improving patient outcomes and quality of life for all cancer patients. We plan to drive innovation in healthcare by offering proprietary molecular tests that address unmet clinical needs from cancer screening to treatment and monitoring. We believe that by investigating novel disease pathways, such as B. Tumor “stemness” that will help care teams better understand the biology of each patient’s cancer, leading to more informed decision-making. For more information, please visit www.accustem.com.

Forward-Looking Statements

This press release contains “forward-looking statements” Forward-looking…